Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4506-4513
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4506
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4506
Table 1 Changes of tumor markers at different time points
| Indicators | AFP (ng/mL) | CA19-9 (U/mL) | CEA (ng/mL) | CA125 (U/mL) | CA15-3 (U/mL) |
| On admission | 1.64 | 49.09 | 1.30 | 83.80 | 8.50 |
| After the initial treatment | 2.07 | 55.00 | 1.66 | 91.00 | 9.00 |
| After organoid-based treatment | 2.45 | 25.67 | 1.21 | 34.20 | 10.20 |
| 7 months after surgery | 2.37 | 27.41 | 1.36 | 23.95 | 10.60 |
- Citation: He YG, Wang Z, Li J, Xi W, Zhao CY, Huang XB, Zheng L. Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report. World J Gastrointest Oncol 2024; 16(11): 4506-4513
- URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4506.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4506